Patient characteristics and survival of all patients (N = 164)
| Variable . | Total cohort (N = 164), N (%) . | GVHD subtype . | |
|---|---|---|---|
| Classic plus overlap cGVHD (N = 101), N (%) . | aGVHD subtypes plus no GVHD (N = 63), N (%) . | ||
| Pretransplantation characteristics | |||
| Median age, y (range) | 47 (18-69) | 49 (21-67) | 46 (18-69) |
| Sex | |||
| Male (R) | 80 (49) | 49 (49) | 31 (49) |
| Female (R) | 84 (51) | 52 (51) | 32 (51) |
| Female D to male R | 31 (19) | 21 (21) | 10 (19) |
| Race | |||
| White (R/D) | 156 (95)/153 (93) | 94 (93)/92 (91) | 62 (98)/61 (97) |
| Diagnoses | |||
| Acute leukemia | 86 (52) | 49 (49) | 37 (59) |
| Chronic leukemia | 19 (12) | 11 (11) | 8 (13) |
| Lymphoma | 54 (33) | 38 (37) | 16 (25) |
| Other | 5 (3) | 3 (3) | 2 (3) |
| Disease risk* | |||
| Low | 65 (40) | 38 (38) | 27 (43) |
| Intermediate | 30 (18) | 21 (20) | 9 (14) |
| High | 40 (24) | 25 (25) | 15 (24) |
| Missing | 29 (18) | 17 (17) | 12 (19) |
| Stem cell source | |||
| Marrow | 44 (27) | 23 (22) | 21 (33) |
| Peripheral blood stem cells | 120 (73) | 78 (78) | 42 (67) |
| Regimen intensity | |||
| Myeloablative | 111 (68) | 69 (68) | 42 (67) |
| Other | 53 (32) | 32 (32) | 21 (33) |
| Donor type | |||
| Related | 109 (67) | 69 (68) | 40 (63) |
| Unrelated | 55 (33) | 32 (32) | 23 (37) |
| HLA match | |||
| HLA identical sibling | 108 (66) | 68 (67) | 40 (63) |
| HLA matched unrelated | 55 (33) | 32 (32) | 23 (37) |
| Other | 1 (1) | 1 (1) | 0 |
| GVHD prophylaxis | |||
| CSA/MTX | 112 (68) | 72 (71) | 40 (63) |
| CSA/MMF | 50 (31) | 28 (28) | 22 (36) |
| Other | 2 (1) | 1 (1) | 1 (1) |
| TBI | |||
| Yes | 79 (48) | 52 (51) | 27 (43) |
| No | 85 (52) | 49 (49) | 36 (57) |
| CMV | |||
| R/D (+/+) | 63 (38) | 35 (34) | 28 (44) |
| R/D (+/−) | 19 (12) | 12 (12) | 7 (11) |
| R/D (−/+) | 47 (29) | 29 (29) | 18 (29) |
| R/D (−/−) | 35 (21) | 25 (25) | 10 (16) |
| Posttransplantation characteristics | |||
| aGVHD† | |||
| Grade 0 to 2 vs 3 to 4 | 129 (78) vs 32 (20) | 78 (77) vs 21 (21) | 51 (81) vs 11 (17) |
| Grade 0 to 1 vs 2 to 4 | 39 (24) vs 122 (74) | 39 (24) vs 75 (74) | 15 (24) vs 47 (75) |
| Platelets, × 109/L at day 100, median (range) | 110 (10-356) | 105 (17-244) | 112 (10-356) |
| Total bilirubin, mg/dL at day 100, median (range) | 0.8 (0-3.6) | 0.8 (0-2.4) | 0.9 (0.2-3.6) |
| Variable . | Total cohort (N = 164), N (%) . | GVHD subtype . | |
|---|---|---|---|
| Classic plus overlap cGVHD (N = 101), N (%) . | aGVHD subtypes plus no GVHD (N = 63), N (%) . | ||
| Pretransplantation characteristics | |||
| Median age, y (range) | 47 (18-69) | 49 (21-67) | 46 (18-69) |
| Sex | |||
| Male (R) | 80 (49) | 49 (49) | 31 (49) |
| Female (R) | 84 (51) | 52 (51) | 32 (51) |
| Female D to male R | 31 (19) | 21 (21) | 10 (19) |
| Race | |||
| White (R/D) | 156 (95)/153 (93) | 94 (93)/92 (91) | 62 (98)/61 (97) |
| Diagnoses | |||
| Acute leukemia | 86 (52) | 49 (49) | 37 (59) |
| Chronic leukemia | 19 (12) | 11 (11) | 8 (13) |
| Lymphoma | 54 (33) | 38 (37) | 16 (25) |
| Other | 5 (3) | 3 (3) | 2 (3) |
| Disease risk* | |||
| Low | 65 (40) | 38 (38) | 27 (43) |
| Intermediate | 30 (18) | 21 (20) | 9 (14) |
| High | 40 (24) | 25 (25) | 15 (24) |
| Missing | 29 (18) | 17 (17) | 12 (19) |
| Stem cell source | |||
| Marrow | 44 (27) | 23 (22) | 21 (33) |
| Peripheral blood stem cells | 120 (73) | 78 (78) | 42 (67) |
| Regimen intensity | |||
| Myeloablative | 111 (68) | 69 (68) | 42 (67) |
| Other | 53 (32) | 32 (32) | 21 (33) |
| Donor type | |||
| Related | 109 (67) | 69 (68) | 40 (63) |
| Unrelated | 55 (33) | 32 (32) | 23 (37) |
| HLA match | |||
| HLA identical sibling | 108 (66) | 68 (67) | 40 (63) |
| HLA matched unrelated | 55 (33) | 32 (32) | 23 (37) |
| Other | 1 (1) | 1 (1) | 0 |
| GVHD prophylaxis | |||
| CSA/MTX | 112 (68) | 72 (71) | 40 (63) |
| CSA/MMF | 50 (31) | 28 (28) | 22 (36) |
| Other | 2 (1) | 1 (1) | 1 (1) |
| TBI | |||
| Yes | 79 (48) | 52 (51) | 27 (43) |
| No | 85 (52) | 49 (49) | 36 (57) |
| CMV | |||
| R/D (+/+) | 63 (38) | 35 (34) | 28 (44) |
| R/D (+/−) | 19 (12) | 12 (12) | 7 (11) |
| R/D (−/+) | 47 (29) | 29 (29) | 18 (29) |
| R/D (−/−) | 35 (21) | 25 (25) | 10 (16) |
| Posttransplantation characteristics | |||
| aGVHD† | |||
| Grade 0 to 2 vs 3 to 4 | 129 (78) vs 32 (20) | 78 (77) vs 21 (21) | 51 (81) vs 11 (17) |
| Grade 0 to 1 vs 2 to 4 | 39 (24) vs 122 (74) | 39 (24) vs 75 (74) | 15 (24) vs 47 (75) |
| Platelets, × 109/L at day 100, median (range) | 110 (10-356) | 105 (17-244) | 112 (10-356) |
| Total bilirubin, mg/dL at day 100, median (range) | 0.8 (0-3.6) | 0.8 (0-2.4) | 0.9 (0.2-3.6) |
R indicates recipient; D, donor; HLA, human leukocyte antigen; CSA, cyclosporine; MTX, methotrexate; MMF, mycophenolate mofetil; TBI, total body irradiation; and CMV, cytomegalovirus.
Disease risk based on Committee of International Bone Marrow Transplant Registry risk criteria.
Three cases were missing.